Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of frontline ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma (MCL).

Ibrutinib has been a mainstay in the treatment of patients with relapsed/refractory MCL since its FDA approval in 2013. Currently, ibrutinib is being investigated as a first-line treatment for patients with MCL in the large phase III SHINE trial (NCT01776840). The trial is evaluating the safety and efficacy of ibrutinib plus bendamustine and rituximab (Rituxan) in older patients with newly-diagnosed MCL who are not eligible for stem cell transplant. Patients are being randomized to either bendamustine and rituximab plus ibrutinib or bendamustine and rituximab plus placebo.

SHINE has fully enrolled, but no data are available yet. Kahl says that if the trial is positive, it has the potential to change the standard of care for the frontline treatment of older patients with MCL. The trial is expected to read out in 2021.

Videos

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of frontline ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.
 

Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate (ADC) polatuzumab vedotin in lymphoma.

The CD79b humanized monoclonal antibody cleavable peptide linker polatuzumab vedotin is currently being investigated as a single agent, in combination with rituximab (Rituxan), and in combination with bendamustine and rituximab. Polatuzumab vedotin uses the Monomethyl auristatin E (MMAE) payload, which is the same payload used in brentuximab vedotin (Adcetris), says Kahl.

The FDA granted a breakthrough therapy designation to polatuzumab vedotin for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in 2017. The European Medicines Agency also granted the ADC a priority medicines designation. There is an ongoing international phase III trial comparing rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone versus rituximab, cyclophosphamide, and doxorubicin, plus polatuzumab vedotin.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

Brad Kahl, MD

Articles

Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL

Dr. Kahl Discusses Polatuzumab Vedotin in Lymphoma